Last 24.00 NOK
Change Today 0.00 / 0.00%
Volume 0.0
As of 10:25 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

medistim asa (MEDI) Snapshot

Open
24.00 NOK
Previous Close
24.00 NOK
Day High
24.00 NOK
Day Low
24.00 NOK
52 Week High
09/20/13 - 24.90 NOK
52 Week Low
08/1/13 - 18.00 NOK
Market Cap
452.7M
Average Volume 10 Days
955.6
EPS TTM
1.44 NOK
Shares Outstanding
18.9M
EX-Date
04/24/14
P/E TM
16.7x
Dividend
0.80 NOK
Dividend Yield
3.33%
Current Stock Chart for MEDISTIM ASA (MEDI)

Related News

No related news articles were found.

medistim asa (MEDI) Related Businessweek News

No Related Businessweek News Found

medistim asa (MEDI) Details

Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the Unites States, Europe, Asia, and the rest of the world. It offers VeriQ, an intraoperative transit time flow measurement (TTFM) and doppler velocity measurements for intraoperative blood flow and graft patency verification; and VeriQ C, a system that combines ultrasound imaging and TTFM in a single system. The company also provides a range of flow probes, such as TTFM probes; Doppler X-Plore probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis; autoclavable QuickFit and Vascular TTFM probes steam; and PeriVascular transit time probes for measuring blood volume flow for the surgical applications, as well as offers cleaning and sterilization services of flow probes. In addition, it offers imaging probes used with the VeriQ C system to provide images for enhancing intraoperative assessment. Further, the company sells electronic stethoscopes; and distributes and sells third party products. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.

86 Employees
Last Reported Date: 04/14/14
Founded in 1984

medistim asa (MEDI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: 2.3M NOK
Chief Financial Officer
Total Annual Compensation: 1.1M NOK
Chief Executive Officer of Medistim Norge As ...
Total Annual Compensation: 1.4M NOK
Vice President of Development
Total Annual Compensation: 1.0M NOK
Vice President of Production
Total Annual Compensation: 1.1M NOK
Compensation as of Fiscal Year 2013.

medistim asa (MEDI) Key Developments

Medistim ASA Reports Earnings Results for the First Quarter Ended March 31, 2014; Proposes Dividend

Medistim ASA reported earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported sales of NOK 48.857 million compared to NOK 45.507 million a year ago. Operating profit was NOK 7.219 million compared to NOK 7.286 million a year ago. Pre tax profit was NOK 7.240 million compared to NOK 7.798 million a year ago. Profit was NOK 5.203 million or NOK 0.29 per diluted share compared to NOK 5.753 million or NOK 0.32 per diluted share a year ago. Cash flow from operations was NOK 4.044 million compared to NOK 3.467 million a year ago. The board suggested to the General Assembly to pay a dividend of NOK 0.80 per share against NOK 1.10 per share paid a year ago. The company's share is sold ex dividend as of the 24 April 2014 if the General Assembly decides to pay the dividend. An eventual dividend is expected to be paid 8 work days after a decision.

Medi-Stim ASA, Annual General Meeting, Apr 23, 2014

Medi-Stim ASA, Annual General Meeting, Apr 23, 2014., at 10:00 Central European Standard Time. Location: Økernveien 94. Agenda: To approve registration of shareholders or persons represented by proxy; to appoint person to chair the meeting, to sign the protocol, to co-sign the protocol and protocol secretary; to approve of annual report for 2013; to approve profit and loss and balance sheet for 2013; to approve distribution of the profit for the year; to consider the Board of Director's suggests a dividend; to consider the Board of Director's declaration on salary and other remuneration to the management; to consider the Board of Director's declaration; to approve fee to the auditor for 2013; to consider election of board members; to consider fees to the board; to consider leader of the Nomination Committee; to consider general meeting that the leader of the Nomination Committee is compensated; to consider approval of the Board of Director's authorization to increase share capital; and to consider and purchase own shares.

Medi-Stim ASA Announces Earnings Results for the Full Year Ended December 31, 2013

Medi-Stim ASA announced earnings results for the full year ended December 31, 2013. For the period, the company’s operating result before depreciation and write-offs (EBITDA) was NOK 43,309,000 against NOK 47,407,000 a year ago. Profit was NOK 26,536,000 against NOK 30,247,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MEDI:NO 24.00 NOK 0.00

MEDI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MEDI.
View Industry Companies
 

Industry Analysis

MEDI

Industry Average

Valuation MEDI Industry Range
Price/Earnings 16.2x
Price/Sales 2.2x
Price/Book 3.3x
Price/Cash Flow 12.9x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDISTIM ASA, please visit www.medistim.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.